AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05309265 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multidisciplinary vocational rehabilitation intervention
Description: * Information aims to provide tailored information concerning the work law protection (this support is already provided for all patients, regardless the type of disease, and also for citizens);~* Occupational therapy aims to facilitate the reintegration in the previous workplace through the development of a rehabilitation intervention to overcome work difficulties in agreement with employee, employer and occupational physician,~* Social support aims to find new job opportunities (for those who have lost the employment due to the disease) through the giving of support in job search, curriculum preparation, skill analysis, professional retraining and education.
Study NCT05503108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking diet program
Description: Fasting mimicking diet by L-Nutra, a 4-day low caloric, low protein, vegetarian diet 3 days prior to and the day of neoadjuvant chemotherapy administration. The FMD will take place every 4 weeks, thus in total 5 times (2x during ddAC, 3x during Paclitaxel) during the neoadjuvant chemotherapy.
Study NCT05664191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Infusion at 0.1 µg/kg/min at day 1 and day 8
Study NCT05664191 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glucose 5%, solution for injection ECOFLAC at day 1 and day 8
Study NCT05325177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Ibuprofen
Description: (10-5-5 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses
Study NCT05325177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Ibuprofen
Description: (20-10-10 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses
Study NCT05484206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection.
Study NCT06193876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Petitgrain and ylang-ylang essential oil
Description: Petitgrain and ylan-ylang essential oil will be dropped to the handchief and students will smell it 3 times in a day.
Study NCT06193876 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Petitgrain and ylang-ylang essential oil
Description: Petitgrain and ylan-ylang essential oil will be dropped to the handchief and students will smell it 3 times in a day.
Study NCT05734794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab dose: 4 doses of 375 mg/m2 rituximab at 1-week intervals( within +7 days), associated with trimethoprim-sulfamethoxazole(25-50 mg/kg/day orally twice per day, 3 days per week. If the patient is not allergic) for three months from the first rituximab dosing date(Day 1). Four doses of rituximab are necessary whether the patient achieves complete remission.
Study NCT05734794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid
Description: Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks. Vitamin D and calcium(adjusted according to the blood calcium level) were administered for three months.
Study NCT04731649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families Talking Together Plus (FTT +)
Description: FTT + consists of three online intervention sessions of approximately 60-90 minutes each, that cover content from nine modules designed to teach parents effective communication skills, build parent-adolescent relationships, help parents develop successful monitoring strategies, and teach adolescents assertiveness, refusal skills, and how to use a condom correctly and every time.
Study NCT05122416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan examination (S)
Description: A FibroScan examination with the Exploratory S probe.
Study NCT05122416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan examination (M)
Description: A FibroScan examination with the Optimized M probe.
Study NCT05122416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan examination (XL)
Description: A FibroScan examination with the Exploratory XL probe.
Study NCT05122416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan examination (Standard M)
Description: A FibroScan examination with the Standard M probe.
Study NCT06338020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive variable-resistance training
Description: The training was conducted thrice weekly for eight successive weeks under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.~The training protocol included maximum voluntary concentric knee flexor/extensor actions. Three sets of five to 10 repetitions of maximum-effort concentric action at angular speeds of 240, 180, and 120 degrees/second.~The training started with a 10-minute warm-up exercise and ended up with a 5-minute cool-down exercise.
Study NCT06338020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: The program encompassed the standard exercises for survivors of ALL (flexibility, graduated active strengthening, and conditioning exercises). The training was conducted for 45 minutes, two times a week for six successive weeks.
Study NCT06039787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: single bout of moderate intensity continuous training (MICT)
Description: the MICT consists of 60 min continuous cycling
Study NCT06039787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: single bout of High Intensity Interval Training (HIIT)
Description: HIIT consists of 10-min warm-up at the power output corresponding to 50% peak power output (PPO), 4 x 4-min intervals at a power output corresponding to 75% PPO with a 4-min active resting period at 30% PPO to recover
Study NCT06039787 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: waiting control
Description: sitting in a waiting room for 60 min
Study NCT05078710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: 160mg once a week for 24 weeks
Study NCT06479044 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Herrmann Brain Model
Description: The test comprises 120 multiple-choice items on academic, daily, and professional scenarios
Study NCT06218017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen fist
Description: Patients in the two study group first underwent a 10-minute session of high-flow nasal oxygen (50 L/min) followed by the utilization of the standard low-flow nasal oxygen (4 L/min) or underwent a 10-minute session of standard low-flow nasal oxygen (4 L/min) followed by the utilization of the high-flow nasal oxygen (50 L/min).
Study NCT06218017 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal oxygen later
Description: Patient in this group underwent a 10-minute session of standard low-flow nasal oxygen (4 L/min) followed by the utilization of the high-flow nasal oxygen (50 L/min)
Study NCT06651697 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy with full bladder or empty bladder protocols
Study NCT06651697 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Radiation therapy with full bladder or empty bladder protocols
Study NCT04298567 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto,Bay 59-7939)
Description: Rivaroxaban (2.5 mg \[BID\])
Study NCT04298567 — intervention group
Intervention type: DRUG
Intervention: Acetylsalicylic acid(ASA)
Description: ASA (75mg \[QD\]; dose according to local label.
Study NCT06491121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology supported High Intensity Training
Description: patients will perform a 12-week HIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory interval, general resistance, and core muscle strength training, all at high intensity. phase 2 is a similar 12-week HIT program at home, supported by a smartphone application
Study NCT06491121 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Training
Description: patients will perform a 12-week MIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory continuous load, general resistance and core muscle training, all at moderate intensity. Phase 2 is a similar 12-week MIT program at home with an exercise program on paper.
Study NCT06491121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Training
Description: patients will perform a 12-week HIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory interval, general resistance, and core muscle strength training, all at high intensity. phase 2 is a similar 12-week HIT program at home with an exercise program on paper.
Study NCT06657807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online CBT
Description: Online CBT targeting anxiety in pediatric asthma
Study NCT06667921 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound will be used to measure the hyomental distance in neutral position (HMDRn), hyomental distance in extended position (HMDRe), (HMDR) and (DSE).
Study NCT06670079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy + incentives for therapy session attendance
Description: Prolonged exposure therapy plus incentives for therapy session attendance
Study NCT06669806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIPS Stent Graft
Description: a covered TIPS stent graft
Study NCT05809986 — intervention group
Intervention type: OTHER
Intervention: Ofatumumab
Description: There is no treatment allocation. Ofatumumab will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis
Study NCT05699837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audio or visual alpha (10Hz) stimulation
Description: Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights, to deliver rhythmic 10Hz or non-rhythmic stimulation
Study NCT06670066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Talk Birth Control
Description: Let's Talk is an innovative, multi-level intervention addressing adolescents and providers that includes both in-person and online components and is feasible to implement in clinical settings. The three core components are: (1) a printed contraceptive decision aid (CDA) with a QR code linking to the Method Explorer (ME) page on Power to Decide's online birth control website, Bedsider; (2) the Bedsider ME, with information on the full range of contraceptive methods and a personalized method comparison feature; and (3) an online training for providers on Patient-centered Contraceptive Counseling (PCCC), including use of the CDA to support shared decision-making with adolescents.
Study NCT05646680 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: two step adnexectomy
Description: instead of standard resection of salpinx and ovary, they are now separately excised
Study NCT06678789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Nicotine Dose
Description: Will receive a 5-week supply of 6 mg Zyn pouches. Those who smoke 5-20 cigarettes per day will receive 1 tin per day = 35 tins, whereas those who smoke more will receive 2 tins/day \[70 tins\])
Study NCT06678789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Nicotine Dose
Description: Will receive a 5-week supply of 3 mg Zyn pouches. Those who smoke 5-20 cigarettes per day will receive 1 tin per day = 35 tins, whereas those who smoke more will receive 2 tins/day \[70 tins\])
Study NCT06668311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: play dough
Description: 1. Children and families will be informed about the purpose of the study and their verbal and written consent will be obtained.~2. The first part of the Patient Information Form will be completed for children who accept the study.~3. The second part of the Patient Information Form will be completed five minutes before nebulizer treatment.~4. Five minutes before nebulizer treatment, play dough will be given to the child.~5. The child will be allowed to play with the play dough during the nebulizer treatment.~6. The second part of the Patient Information Form will be filled in at the 5th minute of the treatment and after the treatment is over.~7. The application will take approximately 15 minutes.
Study NCT06668311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: picture book reading
Description: 1. Children and families will be informed about the purpose of the study and their verbal and written consent will be obtained.~2. The first part of the Patient Information Form will be completed for children who accept the study.~3. The second part of the Patient Information Form will be completed five minutes before nebulizer treatment.~4. Five minutes before nebulizer treatment, the child will be given a picture book.~5. Picture book will be read to the child during the treatment.~6. The second part of the Patient Information Form will be filled in at the 5th minute of the treatment and after the treatment is over.~7. The application will take approximately 15 minutes.
Study NCT05016245 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TheraSphere™ Yttrium-90 Glass Microspheres
Description: TheraSphere™ Yttrium-90 Glass Microspheres TheraSphere™ is steam sterilized and supplied in 6 standard dose sizes: 3 GBq, 5 GBq, 7 GBq, 10 GBq, 15 GBq, 20 GBq. Custom dose sizes are also available in 0.5 GBq increments between 3 and 20 GBq.~TheraSphereTM is supplied with the following accessories:~Administration Set Administration Accessory Kit
Study NCT05016245 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional Transarterial Chemoembolization(cTACE)
Description: conventional Transarterial Chemoembolization(cTACE) is comprised of an anti-neoplastic agent(s) (i.e. cisplatin), lipiodol and embolic agent(s). The choice of agent(s) to be used is per usual local site practice. Chemotherapy agents can be as a single agent or used in combination, as per local practice.
Study NCT05501860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-920
Description: AG-920 Sterile Topical Ophthalmic Solution
Study NCT05501860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Sterile Topical Ophthalmic Solution
Study NCT05048732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FluorApoTrace
Description: -The dose of 18F-FluorApoTrace to be given is 5 mCi
Study NCT04674176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 550 mg of Rifaximin 3 times a day for 12 days at the start of the diet.
Study NCT06172010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection
Study NCT05484206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection.
Study NCT06172010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin and levofloxacin
Description: antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection
Study NCT05272098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A will receive myofascial release therapy + conventional physical therapy
Description: myofascial release therapy (4 sessions per week). It soft, deep and non-manipulative form of treatment that involves the application of gentle pressure while stretching the body's connective tissue. A specialized form of touch, somatic sense, and specific body movement protocols are the three steps involved in the myofascial release therapy + hot pack (15min) + back care advice and postural modification. A total of 45 min session four times a week.
Study NCT05272098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B will receive endurance training of the trunk extensor muscles + conventional physical therapy
Description: It will be treated with endurance training of trunk extensor muscles. Erector spinae and latissimus dorsi will be included. The exercise protocol will be in four levels Bilateral shoulder left in prone position+ contralateral arm and leg lift in prone position+ both hands behind head and bilateral shoulder lift +bilateral shoulder lift with arm fully elevated + Hot pack (10 min) + back care advice and postural modification. A total of 45 min sessions four times a week.
Study NCT01249105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Taken orally once a week
Study NCT04913363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green space
Description: Green space in which activities take place
Study NCT05413213 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory rehabilitation program
Description: Experimental group: Ambulatory rehabilitation program based on mobilization and muscular solicitation.
Study NCT05413213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ambulatory rehabilitation program
Description: Experimental group: Ambulatory rehabilitation program based on mobilization and muscular solicitation.
Study NCT05307640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CG-Well
Description: CG-Well is a web \& phone based psychosocial intervention that teaches caregivers how to obtain information, education \& support
Study NCT05307640 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Information Support & Referral (ISR)
Description: Attention control group that receives phone calls and modules from the Brain Injury Association of America.
Study NCT06740162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE Program
Description: The PACE program is a 16-week inclusive exercise program taught and adapted by certified Inclusive Fitness Specialists. Study participants, called athletes, will engage in the fitness class with non-study participants with and without disabilities. Athlete participants will also meet weekly with their coaches (also study participants) to discuss goal setting and interact with the web-based dashboard.
Study NCT06747962 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A1 pulley release and pull out tenolysis
Description: A short transverse incision will be made over the proximal or distal palmar crease, according to the digit involved. Blunt dissection will be used to spread the subcutaneous tissue and the palmar fascia to expose the A1 pulley. The digital nerves and vessels will be retracted and protected. The proximal edge of the A1 pulley will be identified and a scalpel blade will be used to divide the entire A1 pulley under direct vision. Flexor digitorum superficialis and flexor digitorum profundus tendons or flexor pollicis longus tendon (for the thumb) will be gently pulled out of the wound with two mosquito forceps to break any adhesions. The wound will be closed primarily with sutures. The patient will be asked to actively move the digit to confirm complete relief of triggering.The wound will be closed primarily with sutures.
Study NCT06747962 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Simple A1 pulley release
Description: A short transverse incision will be made over the proximal or distal palmar crease, according to the digit involved. Blunt dissection will be used to spread the subcutaneous tissue and the palmar fascia to expose the A1 pulley. The digital nerves and vessels will be retracted and protected. The proximal edge of the A1 pulley will be identified and a scalpel blade will be used to divide the entire A1 pulley vision. After release, the patient will be asked to actively move the digit to confirm complete relief of triggering.The wound will be closed primarily with sutures.
Study NCT06769620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORT247
Description: ORT247 will be provided to study sites in single-use, sterile vials for infusion. Each dose will be prepared with normal saline for infusion.
Study NCT06769620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consists of normal saline
Study NCT06757283 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV
Description: Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.)
Study NCT06757283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV
Description: Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.)
Study NCT06776978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active treatment
Description: Participants receive anodic tDCS using a battery-driven Eldith (neuroConn GmbH) Programmable Direct Current Stimulator with surface-soaked sponge electrodes (5×7 cm). A constant current of 2 mA is applied for 20 minutes per session. The stimulation targets the left frontal region (F5 of the extended International 10-20 EEG system), corresponding to Broca's area, while the reference electrode is placed over the contralateral frontopolar cortex. tDCS is performed for 10 daily sessions over two consecutive weeks (5 days per week).